2024年度论文（SCI收录）

1. Liu Y, Pan R, Ouyang Y, Gu W, Xiao T, Yang H, Tang L, Wang H, Xiang B, Chen P.* Pyroptosis in health and disease: mechanisms, regulation and clinical perspective. Signal Transduct Target Ther. 2024 Sep 20;9(1):245. (IF: 40.8) （向波组）

2. Zhu Y, Jian X, Chen S, An G, Jiang D, Yang Q, Zhang J, Hu J, Qiu Y, Feng X, Guo J, Chen X, Li Z, Zhou R, Hu C, He N, Shi F, Huang S, Liu H, Li X, Xie L, Zhu Y, Zhao L, Jiang Y, Li J, Wang J, Qiu L, Chen X, Jia W, He Y, Zhou W.* Targeting gut microbial nitrogen recycling and cellular uptake of ammonium to improve bortezomib resistance in multiple myeloma. Cell Metab. 2024 Jan 2;36(1):159-175.e8. (IF: 29.0) （周文组）

3. Lin X, Kang K, Chen P, Zeng Z, Li G, Xiong W, Yi M, Xiang B.* Regulatory mechanisms of PD-1/PD-L1 in cancers. Mol Cancer. 2024 May 18;23(1):108. (IF: 27.7) （向波组）

4. He R, Liu Y, Fu W, He X, Liu S, Xiao D, Tao Y.* Mechanisms and cross-talk of regulated cell death and their epigenetic modifications in tumor progression. Mol Cancer. 2024 Nov 29;23(1):267. (IF: 27.7) （陶永光组）

5. Wu Z, Zhou Y, Hou X, Liu W, Yin W, Wang L, Cao Y, Jiang Z, Guo Y, Chen Q, Xie W, Wang Z, Shi N, Liu Y, Gao X, Luo L, Dai J, Ren C, Jiang X.* Construction of functional neural network tissue combining CBD-NT3-modified linear-ordered collagen scaffold and TrkC-modified iPSC-derived neural stem cells for spinal cord injury repair. Bioactive Materials. 2024 Feb 3;35:242-258. (IF: 18.2) （任彩萍组）

6. Wang D, Tang L, Chen M, Gong Z, Fan C, Qu H, Liu Y, Shi L, Mo Y, Wang Y, Yan Q, Chen P, Xiang B, Liao Q, Zeng Z, Li G, Wu SX, Xiong W.* Nanocarriers Targeting Circular RNA ADARB1 Boost Radiosensitivity of Nasopharyngeal Carcinoma through Synergically Promoting Ferroptosis. ACS Nano. 2024;18(45):31055-31075. (IF: 15.8) （熊炜组）

7. Wang H, Shu L, Lv C, Liu N, Long Y, Peng X, Ling H, Tao T, Tang J, Cheng Y, Liu S, Xiao D, Tao Y*.** BRCC36 Deubiquitinates HMGCR to Regulate the Interplay Between Ferroptosis and Pyroptosis. Adv Sci. 2024 Mar;11(11):e2304263. (IF: 15.1) （陶永光组）

8. Zhi Y, Wang Q, Zi M, Zhang S, Ge J, Liu K, Lu L, Fan C, Yan Q, Shi L, Chen P, Fan S, Liao Q, Guo C, Wang F, Gong Z, Xiong W, Zeng Z.* Spatial Transcriptomic and Metabolomic Landscapes of Oral Submucous Fibrosis-Derived Oral Squamous Cell Carcinoma and its Tumor Microenvironment. Adv Sci. 2024 Jan 16;e2306515. (IF: 15.1) （熊炜组）

9. Zhou Y, Peng X, Fang C, Peng X, Tang J, Wang Z, Long Y, Chen J, Peng Y, Zhang Z, Zhou Y, Tang J, Liao J, Xiao D, Tao Y, Shi Y, Liu S.** Histones Methyltransferase NSD3 Inhibits Lung Adenocarcinoma Glycolysis Through Interacting with PPP1CB to Decrease STAT3 Signaling Pathway. Adv Sci (Weinh). 2024 Aug 9;0(0):e2400381. (IF: 15.1) （陶永光组）

10. Ge J, Meng Y, Guo J, Chen P, Wang J, Shi L, Wang D, Qu H, Liao Q, Fan C, Zhang S, Zhou M, Xiang B, Wang F, Tan M, Gong Z, Xiong W, Zeng Z.* Human papillomavirus-encoded circular RNA circE7 promotes immune evasion in head and neck squamous cell carcinoma. Nat Commun. 2024 Oct 4;15(1):8609. (IF: 14.7) （曾朝阳组）

11. Chen L, Ning J, Linghu L, Tang J, Liu N, Long Y, Sun J, Lv C, Shi Y, Xiao D, Tao T, Cao Y, Liu S, Li G, Zhang B, Tao Y.** USP13 facilitates a ferroptosis-to-autophagy switch by activation of the NFE2L2/NRF2-SQSTM1/p62-KEAP1 axis dependent on the KRAS signaling pathway. Autophagy. 2024 Oct 3;doi: 10.1080/15548627.2024.2410619. (IF: 14.6) （陶永光组）

12. Shi F, Shang L, Zhou M, Lv C, Li Y, Luo C, Lu J, Tang M, Luo X, Xu J, Fan J, Zhou J, Gao Q, Wu W, Jia W, Wang H, Cao Y.* Epstein-Barr virus-driven metabolic alterations contribute to the viral lytic reactivation and tumor progression in nasopharyngeal carcinoma. Journal of Medical Virology. 2024 May;96(5):e29634. (IF: 12.7) （石峰组）

13. Guan F, Wu X, Zhou J, Lin Y, He Y, Fan C, Zeng Z, Xiong W.* Mitochondrial transfer in tunneling nanotubes-a new target for cancer therapy. J Exp Clin Cancer Res. 2024 May 21;43(1):147. (IF: 11.4) （熊炜组）

14. Zhou Z, Qu C, Zhou P, Zhou Q, Li D, Wu X, Yang L.* Extracellular vesicles activated cancer-associated fibroblasts promote lung cancer metastasis through mitophagy and mtDNA transfer. J Exp Clin Cancer Res. 2024 Jun 3;43(1):158. (IF: 11.3) （杨力芳组）

15. Qu H, Wang Y, Yan Q, Fan C, Zhang X, Wang D, Guo C, Chen P, Shi L, Liao Q, Zhou M, Wang F, Zeng Z, Xiang B, Xiong W.* CircCDYL2 bolsters radiotherapy resistance in nasopharyngeal carcinoma by promoting RAD51 translation initiation for enhanced homologous recombination repair. J Exp Clin Cancer Res. 2024 Apr 23;43(1):122. (IF: 11.3) （熊炜组）

16. Jia S, Bode AM, Chen X, Luo X.* Unlocking the potential: Targeting metabolic pathways in the tumor microenvironment for Cancer therapy. Biochim Biophys Acta Rev Cancer. 2024 Sep;1879(5):189166. (IF: 11.2) （罗湘建组）

17. Kang K, Lin X, Chen P, Liu H, Liu F, Xiong W, Li G, Yi M, Li X, Li Y, Wang H, Xiang B.* T cell exhaustion in human cancers. Biochim Biophys Acta Rev Cancer. 2024 Sep;1879(5):189162. (IF: 11.2) （向波组）

18. X Long, Z Zhang, Y Li, K Deng, W Gao, M Huang, X Wang, X Lin, X She, Y Zhao, M Zhang, C Huang, S Wang, Y Du, P Du, S Liu, M Wu.* ScRNA-seq reveals novel immune-suppressive T cells and investigates CMV-TCR-T cells cytotoxicity against GBM. The Journal for ImmunoTherapy of Cancer. 2024 Apr 30;12(4):e008967. (IF: 10.9) （武明花组）

19. Xie C, Zhong L, Feng H, Wang R, Shi Y, Lv Y, Hu Y, Li J, Xiao D, Liu S, Chen Q, Tao Y.** Exosomal miR-17-5p derived from epithelial cells is involved in aberrant epithelium-fibroblast crosstalk and induces the development of oral submucosal fibrosis. International Journal of Oral Science. 2024;10.1136/ard-2023-224941. (IF: 10.8) （陶永光组）

20. Tang J, Long G, Xiao D, Liu S, Xiao L, Zhou L, Tao Y.* ATR-dependent ubiquitin-specific protease 20 phosphorylation confers oxaliplatin and ferroptosis resistance. Medcomm. 2024 Jan 1;10.1002/mco2.463. (IF: 10.7) （陶永光组）

21. Long Y, Mao C, Liu S, Tao Y, Xiao D,** Epigenetic modifications in obesity-associated diseases. Medcomm (2020). 2024 Feb;5(2):e496. (IF: 10.7) （陶永光组）

22. Qin S, Xie B, Wang Q, Yang R, Sun J, Hu C, Liu S, Tao Y, Xiao D*.** New insights into immune cells in cancer immunotherapy: from epigenetic modification, metabolic modulation to cell communication. Medcomm (2020). 2024 Jun;5(6):e551. (IF: 10.7) （陶永光组）

23. Ge J, Liu Y, Chen P, Zeng Z, Li G, Xiong W, Yi M, Xiang B.* FOXA1 enhances anti-tumor immunity via repressing interferon induced PD-L1 expression in nasopharyngeal carcinoma. J Immunother Cancer. 2024 Nov 14;12(11). (IF: 10.3) （向波组）

24. Li Z, Zhang X, Liu C, Wu Y, Wen Y, Zheng R, Xu C, Tian J, Peng Q, Zheng X, Wang J, Yan Q, Wei L, Ma J.** Engineering a Nano-drug Delivery System to Regulate m6A Modification and Enhance Immunotherapy in Gastric Cancer. Acta Biomaterialia. 2024 Nov 22;S1742-7061(24)00689-5. (IF: 9.9) （马健组）

25. Liu Y, Yan Q, Zeng Z, Fan C, Xiong W.* Advances and prospects of mRNA vaccines in cancer immunotherapy. Biochim Biophys Acta Rev Cancer. 2024 Mar;1879(2):189068. (IF: 9.7) （熊炜/曾朝阳组）

26. Zhong Y, Shuai Y, Yang J, Zhang M, He T, Zheng L, Peng S, Shuai C.** LOC730101 improves ovarian cancer drug sensitivity by inhibiting autophagy-mediated DNA damage repair via BECN1. Cell Death Dis. 2024;in press. (IF: 9.6) （彭淑平组）

27. Wang F, Liao Q, Qin Z, Li J, Wei Q, Li M, Deng H, Xiong W, Tan M, Zhou M.* Autophagy: a critical mechanism of N6-methyladenosine modification involved in tumor progression and therapy resistance. Cell Death Dis. 2024;15(10):783. (IF: 9.6) （周鸣组）

28. Zhou X, Tao Y, Shi Y.* Unraveling the NLRP family: Structure, function, activation, critical influence on tumor progression, and potential as targets for cancer therapy. Cancer Lett. 2024 Oct 2;605(0):217283. (IF: 9.1) （陶永光组）

29. Xie Y, Zhang L, Wang L, Chen B, Guo X, Yang Y, Shi W, Chen A, Yi J, Tang J, Xiang J.* EphB1 promotes the differentiation and maturation of dendritic cells in non-small cell lung cancer. Cancer Lett. 2024 Feb 1;582:216567. (IF: 9.1) （向娟娟组）

30. Liu S, Li W, Liang L, Zhou Y, Li Y. The regulatory relationship between transcription factor STAT3 and noncoding RNA. Cell Mol Biol Lett. 29(1):4 (2024). (IF: 8.3) (周艳宏组)

31. Guo XT, Yang YY, Tang JQ, Xiang JJ. Ephs in cancer progression: complexity and context-dependent nature in signaling, angiogenesis and immunity. Cell Commun Signal. 22(1):299 (2024). (IF: 8.2) (向娟娟组)

32. Liu YY, Shen L, Li Y, Sun XY, Liang L, Jiang SY, Zhang ZY, Tang XJ, Tao YG, Xie L, Jiang YQ, Cong L. Mutational profile evaluates metastatic capacity of Chinese colorectal cancer patients, revealed by whole-exome sequencing. Genomics. 116:110809 (2024). (IF: 8.2) (李征组)

33. Liu YY, Shen L, Li Y, Sun XY, Liang L, Jiang SY, Zhang ZY, Tang XJ, Tao YG, Xie L, Jiang YQ, Cong L. ETS1-mediated Regulation of SOAT1 Enhances the Malignant Phenotype of Oral Squamous Cell Carcinoma and Induces Tumor-associated Macrophages M2-like Polarization. Int J Biol Sci. 20(9):3372-3392 (2024). (IF: 8.2) (陶永光组)

34. Li M, Wei J, Xue C, Chen S, Zhou XT, Zheng L, Duan Y, Deng H, Fan S, Xiong W, Tang F, Zhou M. BRD7 enhances the radiosensitivity of nasopharyngeal carcinoma cells by negatively regulating USP5-METTL3 axis-mediated homologous recombination repair. Int J Biol Sci. 20(15):6130-6145 (2024). (IF: 8.2) (周鸣组*)

35. Fan CM, Xiong F, Zhang SS, Gong ZJ, Liao QJ, Li GY, Guo C, Xiong W, Huang H, Zeng ZY. Role of adhesion molecules in cancer and targeted therapy. Sci China Life Sci. 67(5):940-957 (2024). (IF: 8.0) (曾朝阳组*)

36. Qin W, Xue C, Li M, Wei J, Zheng L, Chen S, Duan Y, Deng H, Tang F, Xiong W, Zhou M. Ferroptosis: a critical mechanism of N6-methyladenosine modification involved in carcinogenesis and tumor progression. Sci China Life Sci. 67(6):1119–1132 (2024). (IF: 8.0) (周鸣组)

37. Li LY, Tang QL, Ge JS, Wang D, Mo YZ, Zhang YJ, Wang YM, Xiong F, Yan QJ, Liao QJ, Guo C, Wang FY, Zhou M, Xiang B, Zeng ZY, Shi L, Chen P, Wei X. METTL14 promotes lipid metabolism reprogramming and sustains nasopharyngeal carcinoma progression via enhancing m6A modification of ANKRD22 mRNA. Clin Transl Med. 14(7):e1766 (2024). (IF: 7.9) (熊炜组)

38. Hou XC, Ouyang JW, Tang L, Wu P, Deng XY, Yan QJ, Shi L, Fan SQ, Fan CM, Guo C, Liao QJ, Li Y, Wei X, Li ZY, Zeng ZY, Wang FY. KCNK1 promotes proliferation and metastasis of breast cancer cells by activating lactate dehydrogenase A (LDHA) and up-regulating H3K18 lactylation. PLoS Biol. 22(6):e3002666 (2024). (IF: 7.8) (曾朝阳组)

39. Li Y, Liu W, Xu H, Zhou Y, Xie W, Guo Y, Liao Z, Jiang X, Liu J, Ren CP. Aptamers combined with immune checkpoints for cancer detection and targeted therapy: A review. Int J Biol Macromol. 262(Pt 2):130032 (2024). (IF: 7.7) (任彩萍组)

40. Liang L, Gao M, Li W, Tang J, He Q, Zeng F, Cao J, Liu S, Chen Y, Li X, Zhou Y. CircGSK3β mediates PD-L1 transcription through miR-338-3p/PRMT5/H3K4me3 to promote breast cancer cell immune evasion and tumor progression. Cell Death Discov. 10(1):426 (2024). (IF: 7.0) (周艳宏组)

41. Hu X, Zhou P, Peng X, Ouyang Y, Li D, Wu X, Yang L. PXD101 inhibits malignant progression and radioresistance of glioblastoma by upregulating GADD45A. Journal of Translational Medicine. 22(1):1047 (2024). (IF: 6.1) (杨力芳组)

42. Zhu HL, Luo H, Skaug B, Tabib T, Li YN, Tao YG, Matei AE, Lyons MA, Schett G, Lafyatis R, Assassi S, Distler JHW. Fibroblast Subpopulations in Systemic Sclerosis: Functional Implications of Individual Subpopulations and Correlations with Clinical Features. J Invest Dermatol. 144(6):1251-1261.e13 (2024). (IF: 5.9) (陶永光组)

43. Xu W, Li HT, Wang ZY, Kang Y, Zheng LJ, Liu YP, Xu P, Li Z. LINC00152: Potential driver oncogene in pan-cancer. WIREs RNA. 15:e1851 (2024). (IF: 5.9) (李征组)

44. Wen Y, Ye S, Li Z, Zhang X, Liu C, Wu Y, Zheng R, Xu C, Tian J, Shu L, Yan Q, Ai F, Ma J. HDAC6 inhibitor ACY-1215 enhances STAT1 acetylation to block PD-L1 for colorectal cancer immunotherapy. Cancer Immunology Immunotherapy. 73(1):7 (2024). (IF: 5.8) (马健组)

45. Qi FW, Li HX, Gao XW, Wang YF, Qian HY, Li W, Liu SL, Zhou HR, Peng SP, Shuai CJ. Oxygen vacancy healing boosts the piezoelectricity of bone scaffold. Biomaterials Science. 12(2):495-506 (2024). (IF: 5.7) (彭淑平组)

46. Tang J, Peng XT, Xiao DS, Liu S, Tao YG, Shu L. Disulfidptosis-related signature predicts prognosis and characterizes the immune microenvironment in hepatocellular carcinoma. Cancer Cell Int. 24:1 (2024). (IF: 5.3) (陶永光组)

47. Bao SW, Yi M, Xiang B, Chen P.** Antitumor mechanisms and future clinical applications of the natural product triptolide. Cancer Cell Int. 24(1):150 (2024). (IF: 5.3) (向波组)

48. Zeng HL, Ge JS, Meng Y, Wang Q, Yang M, Zeng ZY, Xiong W, Zu XY. Research progress on the role and mechanism of circular RNA in drug resistance of head and neck squamous cell carcinoma. Cancer Drug Resist. 7(0):31 (2024). (IF: 5.2) (熊炜组)

49. Shi S, Wang C, Cai QD, Yang R, Peng MY, Liang HX, Qian BL, Jiang YP, Xiao B, Wang L, Tao YG, Cai J, Zhao ZY. RBM15 drives the progression of lung adenocarcinoma by regulating N6-methyladenosine-mediated LDHA mRNA stability. Life Sci. 358:123146 (2024). (IF: 5.2) (陶永光组)

50. Zhang B, Li W, Cao J, Zhou Y, Yuan X. Prohibitin 2: A key regulator of cell function. Life Sci. 338:122371 (2024). (IF: 5.2) (周艳宏组)

51. Xu H, Yin Y, Li Y, Shi N, Xie W, Luo W, Wang L, Zhu B, Liu W, Jiang X, Ren CP. FLOT2 promotes nasopharyngeal carcinoma progression through suppression of TGF-β pathway via facilitating CD109 expression. iScience. 27(1):108580 (2024). (IF: 5.0) (任彩萍组)

52. Liu H, Li X, Liu W, Zhang C, Zhang S, Zhou X, Bode AM, Luo X. DHRS2-induced SPHK1 downregulation contributes to the cell growth inhibition by Trichothecin in colorectal carcinoma. Biochim Biophys Acta Mol Cell Res. 1871(8):119846 (2024). (IF: 4.9) (罗湘建组)

53. Nasot Rashed, Liu W, Zhou X, Bode AM, Luo X. The role of circadian gene CLOCK in cancer. Biochim Biophys Acta Mol Cell Res. 1871(7):119782 (2024). (IF: 4.9) (罗湘建组)

54. Huang M, Liu YX, Yan QJ, Peng M, Ge JS, Mo YZ, Wang YM, Wang FY, Zeng ZY, Li Y, Fan CM, Xiong W. NK cells as powerful therapeutic tool in cancer immunotherapy. Cell Oncol (Dordr). 47(3):733-757 (2024). (IF: 4.9) (曾朝阳/熊炜组)

55. Chen X, Wu P, Liu ZQ, Li TS, Wu J, Zeng ZY, Guo WJ, Xiong W. Tertiary lymphoid structures and their therapeutic implications in cancer. Cell Oncol (Dordr). 47(5):1579-1592 (2024). (IF: 4.9) (曾朝阳/熊炜组)

56. Lu XX, Mei Y, Fan CM, Chen P, Li XY, Zeng ZY, Li GY, Xiong W, Xiang B, Yi M.** Silencing AHNAK promotes nasopharyngeal carcinoma progression by upregulating the ANXA2 protein. Cell Oncol (Dordr). 47(3):833-850 (2024). (IF: 4.9) (向波组)

57. Li LY, Zhang Y, Tang QL, Wu CY, Yang M, Hu Y, Gong ZJ, Shi L, Guo C, Zeng ZY, Chen P, Xiong W. Mitochondria in tumor immune surveillance and tumor therapies targeting mitochondria. Cell Oncol (Dordr). 47(6):2031-2047 (2024). (IF: 4.9) (熊炜/曾朝阳组)

58. Xue C, Meng H, Niu W, Li M, Wei J, Chen S, Zheng L, Duan Y, Deng H, Tang F, Fan S, Tan M, Xiong W, Zhou M*. TRIM28 promotes tumor growth and metastasis in breast cancer by targeting the BRD7 protein for ubiquitination and degradation. Cell Oncol (Dordr). 2024,47(5):1973–1993. (IF: 4.9) (周鸣组)

59. Long S, Tang J, Liu S, Tao YG. Plasma cell signatures predict prognosis and treatment efficacy for lung adenocarcinoma. Cell Oncol (Dordr). 2024 Apr;47(2):555-571. (IF: 4.9) (陶永光组)

60. Long S, Tang J, Liu S, Tao YG. Regulation of VEGF A expression and VEGF A targeted therapy in malignant tumors. Journal of Cancer Research and Clinical Oncology. 2024;150:221. (IF: 4.9) (李征组)

61. Xie W, Liu W, Wang L, Li S, Liao Z, Xu H, Li Y, Jiang X, Ren C. Embryonic stem cell related gene regulates alternative splicing of transcription factor 3 to maintain human embryonic stem cells' self-renewal and pluripotency. Stem Cells. 2024;42(6):540-553. (IF: 4.9) (任彩萍组)

62. Chen S, Li M, Xue C, Zhou X, Wei J, Zheng L, Duan Y, Deng H, Tang F, Xiong W, Xiang B*, Zhou M*. Validation of Core Ingredients and Molecular Mechanism of Cinobufotalin Injection Against Liver Cancer. Drug Design, Development and Therapy. 2024;18: 1321-1338. (IF: 4.8) (周鸣组)

63. Zhang X, Li Z, Peng Q, Liu C, Wu Y, Wen Y, Zheng R, Xu C, Tian J, Zheng X, Yan Q, Wang J*, Ma J*. Epstein-Barr virus suppresses N6-Methyladenosine modification of TLR9 to promote immune evasion. Journal of Biological Chemistry. 2024 Mar 25; 300(5): 107226. (IF: 4.8) (马健组)

64. Yin W, Jiang Z, Guo Y, Cao Y, Wu Z, Zhou Y, Chen Q, Liu W, Jiang X, Ren C. Identification of Anoikis-Related Genes in Spinal Cord Injury: Bioinformatics and Experimental Validation. Mol Neurobiol. 2024;61(11):8531-8543. (IF: 4.7) (任彩萍组)

65. Luo LJ, Zeng ZH, Li T, Liu XM, Cui YN, Tao YG, Li Y, Chen Y*. TET2 stabilized by deubiquitinase USP21 ameliorates cigarette smoke-induced apoptosis in airway epithelial cells. iScience. 2024/03/05;27. (IF: 4.6) (陶永光组)

66. Wang L, Yin N, Shi W, Xie Y, Yi J, Tang Z, Tang J, Xiang J. Splicing inhibition mediated by reduced splicing factors and helicases is associated with the cellular response of lung cancer cells to cisplatin. Comput Struct Biotechnol J. 2024;23:648–658. (IF: 4.5) (向娟娟组)

67. Zhang JR, Chen MJ, Yang YX, Liu ZQ, Guo WG, Xiang PJ, Zeng ZY, Wang D, Xiong W. Amino acid metabolic reprogramming in the tumor microenvironment and its implication for cancer therapy. J Cell Physiol. 2024 Nov;239(11):e31349. (IF: 4.5) (熊炜/曾朝阳组)

68. Cao D, Sun W, Li X, Jian L, Zhou X, Bode AM, Luo X. The role of novel protein acylations in cancer. Eur J Pharmacol. 2024 Sep 15;979:176841. (IF: 4.3) (罗湘建组)

69. Wei J, Li M, Chen S, Xue C, Zheng L, Duan Y, Deng H, Fan S, Xiong W, Zhou M*. CircBRD7 attenuates tumor growth and metastasis in nasopharyngeal carcinoma via epigenetic activation of its host gene. Cancer Sci. 2024;115(1): 139-154. (IF: 4.3) (周鸣组)

70. Xie W, Liu W, Wang L, Zhu B, Zhao C, Liao Z, Li Y, Jiang X, Liu J, Ren C. Roles of THEM4 in the Akt pathway: a double-edged sword. J Zhejiang Univ Sci B. 2024;25(7):541-556. (IF: 4.1) (任彩萍组)

71. Xie D, Huang H, Guo Y, Jiang Z, Kuang Y, Huang H, Liu W, Wang L, Xin Z, Wang B, Ren C, Jiang X. Integrated profiling identifies ferredoxin 1 as an immune-related biomarker of malignant phenotype in glioma. Heliyon. 2024;10(5):e26976. (IF: 3.9) (任彩萍组)

72. Liang L, Yue C, Li W, Tang J, He Q, Zeng F, Cao J, Liu S, Chen Y, Li X, Zhou Y. CD38 symmetric dimethyl site R58 promotes malignant tumor cell immune escape by regulating the cAMP-GSK3beta-PD-L1 axis. Heliyon. 2024 Sep 19;10(19):e37958. (IF: 3.9) (周艳宏组)

73. Wen LZ, Xie B, Li H, Huang J, Shi Y, Tao YG, Chen YB. Ginsenoside Rb1 regulates CPT1A deacetylation to inhibit intramuscular fat infiltration after rotator cuff tear. iScience. 2024;27:110331. (IF: 3.3) (李征组)

74. Wang QY, Xie B, Sun JY, Li ZS, Xiao DS, Tao YG, She XL. An Investigation of the Immune Microenvironment and Genome during Lung Adenocarcinoma Development. J Cancer. 2024/02/19;15. (IF: 3.3) (陶永光组)

75. Wen LZ, Xie B, Li H, Huang J, Shi Y, Tao YG, Chen YB. EP300 through upregulating the expression of vimentin to promote the progression of chordoma. Neurosurg Focus. 2024 May;56(5):E17. (IF: 3.3) (陶永光组)

76. Chen YB, Ning JL, Long S, Wen LZ, Yan BK, Wang ZL, Hu XH, Zhou XK, Tao YG, Xia JX, Huang J. CPLX2 is a novel tumor suppressor and improves the prognosis in glioma. J Neurooncol. 2024/03/01;167. (IF: 3.2) (陶永光组)

77. Shi W, Tang J, Xiang J. Therapeutic strategies for aberrant splicing in cancer and genetic disorders. Clin Genet. 2024 Apr;105(4):345-354. (IF: 2.9) (向娟娟组)

78. Wu CY, Li LY, Tang QL, Liao QJ, Chen P, Guo C, Zeng ZY, Xiong W. Role of m6A modifications in immune evasion and immunotherapy. Med Oncol. 2024 May 18;41(6):159. (IF: 2.8) (熊炜/曾朝阳组)

79. Tang L, Chen MJ, Wang D, He Y, Ge GL, Zeng ZY, Shu JY, Guo WJ, Wu SX, Xiong W. Doxorubicin and iron-doped mesoporous silica nanoparticles for chemodynamic therapy and chemotherapy of breast cancer. New J Chem. 2024 Oct 21;48(39):17294-17309. (IF: 2.7) (熊炜组)

80. Ge G, Tu HY, Wang D, Chen MJ, Zeng ZY, Guo C, Wu X, Xiong W. Fe-doped carbon dot liposome enhanced radiosensitivity of tumor cells by inducing ferroptosis. New Journal of Chemistry. 2024, 48, 3181. (IF: 2.7) (熊炜组)